NASDAQ:MDWD MediWound (MDWD) Stock Price, News & Analysis $19.80 +0.43 (+2.22%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$19.11▼$19.8650-Day Range$13.46▼$21.1652-Week Range$7.10▼$24.00Volume29,364 shsAverage Volume110,791 shsMarket Capitalization$183.74 millionP/E RatioN/ADividend YieldN/APrice Target$31.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MediWound alerts: Email Address MediWound MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside58.2% Upside$31.33 Price TargetShort InterestBearish8.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.81 out of 5 starsMedical Sector680th out of 936 stocksMedicinals & Botanicals Industry5th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMediWound has only been the subject of 2 research reports in the past 90 days.Read more about MediWound's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.22% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently increased by 103.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 3.8 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MediWound this week, compared to 1 article on an average week.Search Interest10 people have searched for MDWD on MarketBeat in the last 30 days. MarketBeat Follows2 people have added MediWound to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of MediWound is held by insiders.Percentage Held by Institutions46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MediWound's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to remain at ($1.93) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediWound has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MediWound's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About MediWound Stock (NASDAQ:MDWD)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Read More MDWD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDWD Stock News HeadlinesJuly 19, 2024 | americanbankingnews.comMediWound (NASDAQ:MDWD) Upgraded to Sell by StockNews.comJuly 17, 2024 | americanbankingnews.comMediWound (NASDAQ:MDWD) Given "Buy" Rating at HC WainwrightJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 16, 2024 | globenewswire.comMediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator ProgramJuly 15, 2024 | prnewswire.comMölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound LtdJuly 15, 2024 | globenewswire.comMediWound Announces $25 Million Strategic Private Placement FinancingMay 29, 2024 | finanznachrichten.deMediWound Ltd.: MediWound Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 29, 2024 | investorplace.comMDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | globenewswire.comMediWound Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 28, 2024 | money.usnews.comMediWound LtdMay 28, 2024 | msn.comMediWound Q1 2024 Earnings PreviewMay 22, 2024 | globenewswire.comMediWound to Report First Quarter 2024 Financial ResultsMay 13, 2024 | finance.yahoo.comInvestors in MediWound (NASDAQ:MDWD) have seen decent returns of 65% over the past yearApril 25, 2024 | globenewswire.comMediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care ConferencesApril 17, 2024 | finance.yahoo.comStrength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?March 24, 2024 | finance.yahoo.comMediWound Ltd. (NASDAQ:MDWD) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?March 23, 2024 | seekingalpha.comMediWound Ltd. (MDWD) Q4 2023 Earnings Call TranscriptSee More Headlines Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/29/2024Today7/27/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees80Year Founded2001Price Target and Rating Average Stock Price Target$31.33 High Stock Price Target$36.00 Low Stock Price Target$28.00 Potential Upside/Downside+58.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,720,000.00 Net Margins-64.24% Pretax Margin-63.21% Return on Equity-21.67% Return on Assets-10.23% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.83 Sales & Book Value Annual Sales$18.69 million Price / Sales9.83 Cash FlowN/A Price / Cash FlowN/A Book Value$3.43 per share Price / Book5.77Miscellaneous Outstanding Shares9,280,000Free Float8,430,000Market Cap$183.74 million OptionableOptionable Beta0.81 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Ofer Gonen B.Sc. (Age 51)Chief Executive Officer Comp: $649kMs. Hani Luxenburg (Age 51)Chief Financial Officer Comp: $235kMr. Yaron Meyer Adv. (Age 45)Executive VP, General Counsel & Corporate Secretary Comp: $299kDr. Ety Klinger MBA (Age 62)Ph.D., Chief Research & Development Officer Comp: $377kDr. Lior Rosenberg M.D. (Age 78)Co-Founder Comp: $727kDr. Shmulik Hess Ph.D. (Age 51)COO & Chief Commercial Officer Mr. Barry J. Wolfenson (Age 57)Executive Vice President of Strategy & Corporate Development Dr. Robert J. Snyder CWS (Age 74)D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer More ExecutivesKey CompetitorsMenlo TherapeuticsNASDAQ:FOMXChromaDexNASDAQ:CDXCNatural Alternatives InternationalNASDAQ:NAIIMannatechNASDAQ:MTEXSNDLNASDAQ:SNDLView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 22,010 shares on 7/26/2024Ownership: 0.237%Rosalind Advisors Inc.Bought 27,500 shares on 7/12/2024Ownership: 5.533%Essex Investment Management Co. LLCBought 93,705 shares on 5/3/2024Ownership: 1.396%Janney Montgomery Scott LLCBought 29,948 shares on 5/1/2024Ownership: 0.316%View All Institutional Transactions MDWD Stock Analysis - Frequently Asked Questions How have MDWD shares performed this year? MediWound's stock was trading at $10.17 at the beginning of 2024. Since then, MDWD shares have increased by 94.7% and is now trading at $19.80. View the best growth stocks for 2024 here. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings results on Wednesday, May, 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. The biopharmaceutical company had revenue of $4.96 million for the quarter, compared to analyst estimates of $4.65 million. MediWound had a negative trailing twelve-month return on equity of 21.67% and a negative net margin of 64.24%. When did MediWound's stock split? MediWound shares reverse split on the morning of Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. Who are MediWound's major shareholders? Top institutional investors of MediWound include Rosalind Advisors Inc. (5.53%) and Bank of New York Mellon Corp (0.24%). How do I buy shares of MediWound? Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA) and Mastercard (MA). This page (NASDAQ:MDWD) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
